- Updated data from a phase 2 trial found that BridgeBio Pharma's ( NASDAQ: BBIO ) BBP-418 led to i mprovements over 12 months in those with limb-girdle muscular dystrophy type 2i (LGMD2i) .
- Results showed that after 12 months of treatment, there was increased glycosylation of alpha-dystroglycan (?DG) in all dose cohorts; greater than 75% reduction in creatine kinase sustained over 12 months; and improvements in key functional measures such as the north star assessment for dysferlinopathy (NSAD) and 100-meter walk test (10MWT).
- BridgeBio ( BBIO ) aims to start a phase 3 trial of BBP-418 in 2023.
- Seeking Alpha's Quant Rating views BridgeBio Pharma ( BBIO ) as a buy with high marks for momentum and growth .
For further details see:
BridgeBio reports good phase 2 results on candidate for limb-girdle muscular dystrophy